Beam Therapeutics Inc. Common Stock (BEAM) Financials
Key financial figures for Beam Therapeutics Inc. Common Stock (Q3 2026).
Beam reported a Q3 2026 net loss of $134.4 million ($1.28 per share) with $1.0 billion in cash and marketable securities, and reiterated a risto-cel BLA submission as early as year-end 2026. Net loss was $134.4 million, or $1.28 per share, versus $112.6 million, or $1.10 per share, in Q3 2025. License and collaboration revenue was $0.3 million versus $9.7 million. Research and development expense was $110.1 million versus $109.8 million; general and administrative expense was $31.5 million versus $26.7 million; loss from operations was $141.3 million versus $126.8 million. Cash, cash equivalents and marketable securities were $1.0 billion at September 30, 2026, versus $1.2 billion at December 31, 2025. On the outlook: Cash, cash equivalents and marketable securities as of September 30, 2026, together with an additional $200 million expected to be drawn from the Sixth Street facility (assuming the applicable conditions are satisfied), are expected to fund operating expenses and capital expenditures into mid-2029. Pipeline timing: updated risto-cel clinical data by year-end 2026; U.S. BLA submission for risto-cel as early as year-end 2026; completion of dosing in the BEAM-302 pivotal cohort in the first half of 2027; BEAM-304 Phase 1/2 dosing to begin in early 2027. Figures are for Q3 2026, as Beam Therapeutics Inc. reported them.
- Revenue
- $307K
- Net Income
- -$134M
- EPS
- $-1.28
- Total Assets
- $1.3B
- Operating Cash Flow
- -$111M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $307K | -$134M | -$1.28 | -46033.22% | -$112M |
| Q2 FY2026 | $490K | -$123M | -$1.18 | -25827.14% | -$69M |
| Q1 FY2026 | $32M | -$94M | -$0.91 | -337.81% | -$131M |
| Q4 FY2025 | $114M | $244M | $2.33 | -15.29% | -$87M |
| Q3 FY2025 | $10M | -$113M | -$1.10 | -1307.6% | -$86M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $140M | -$80M | -$0.81 | -274.57% | -$360M |
| FY2024 | $64M | -$377M | -$4.58 | -654.25% | -$356M |
| FY2023 | $378M | -$133M | -$1.72 | -46.73% | -$183M |
Frequently asked questions
What was Beam Therapeutics Inc.'s revenue last quarter?
Beam Therapeutics Inc. reported revenue of $307.0 thousand for Q3 FY2026, down 96.8% from the same period a year earlier.
Is Beam Therapeutics Inc. profitable?
Not in its most recent reported period. Beam Therapeutics Inc. reported a net loss of $134.4 million for Q3 FY2026, a net margin of -43780.13% on revenue.
How has Beam Therapeutics Inc.'s margin trended?
Operating margin was -46033.22% in Q3 FY2026, compared with -1307.6% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Beam Therapeutics Inc. generate?
Beam Therapeutics Inc. generated free cash flow of -$112.0 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Beam Therapeutics Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.